The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients.
The 2024 recipients consist of 16 individuals who are honored in four categories: lifetime achievement; private brand champion; private brand innovator; and next gen private label leader.